Zacks.com on MSN50m
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock UpBioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, being studied for various oncology indications.
BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback